[**2017 surveillance – Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (2013) NICE guideline CG164**](https://www.nice.org.uk/guidance/cg164)

**Stakeholder consultation comments form - proposal for ‘no update’**

Consultation on the proposal for ‘no update’ opens at: 9am, Tuesday 11 October 2017

Comments on proposal to be submitted: no later than 5pm, Tuesday 24 October 2017

|  |
| --- |
| **Please enter the name of your registered stakeholder or respondent organisation below.**Please use this form for submitting your comments to NICE. 1. Please put each new comment in a new row.
2. Please note – we cannot accept comments forms with attachments such as research articles, letters or leaflets. If we receive forms with attachments we will return them without reading the comments. If you resubmit the comments on a form without attachments, this must be by the consultation deadline.
3. If you wish to draw our attention to published studies, please supply the full reference.
4. NICE is unable to accept comments from non-registered organisations. If you wish your comments to be considered please register via the NICE website or contact the [registered stakeholder organisation](https://www.nice.org.uk/guidance/cg164/update/cg164-update-1/documents/stakeholder-list-2) that most closely represents your interests and pass your comments to them.
 |
| Organisation name – Stakeholder or respondent (if you are commenting as an individual rather than a registered stakeholder or respondent organisation, please leave blank): |  |
| DisclosurePlease disclose whether the organisation has any past or current, direct or indirect links to, or receives funding from, the tobacco industry. |  |
| Name of commentator: |  |

[Developing NICE guidelines: the manual](https://www.nice.org.uk/process/pmg20/chapter/1-introduction-and-overview) gives an overview of the processes used in surveillance reviews of NICE clinical guidelines.

| **ID** | **Questions**  | **Overall response**yes / no | **Comments**Please insert each new comment in a new row |
| --- | --- | --- | --- |
| 1 | **Do you agree with the proposal not to update the guideline?** |  |  |
| 2 | **Do you agree with the proposal to remove the research recommendation:**RR-03 Research is recommended to establish the risk and benefits of MRI surveillance compared with mammography in women over 50 years with a personal history of breast cancer. Studies should include sub-analysis for breast density.  |  |  |
| 3 | **Do you agree with the proposal to remove the research recommendation:**RR-04 What is the clinical and cost effectiveness of aromatase inhibitors (particularly exemestane and letrozole) compared with tamoxifen and raloxifene for reducing the incidence of breast cancer in women with a family history of breast or ovarian cancer? |  |  |
| 4 | **Do you agree with the proposal to remove the research recommendation:**RR-05 Further research is recommended to compare psychosocial and clinical outcomes in women who choose and women who do not choose to have risk-reducing surgery. |  |  |
| 5 | **Do you have any comments on areas excluded from the scope of the guideline?**RR-06 What is the prevalence of BRCA1 mutations in unselected basal phenotype breast cancer compared with unselected triple negative breast cancer? |  |  |
| 6 | **Do you have any comments on areas excluded from the scope of the guideline?** |  |  |
| 7 | **Do you have any comments on equalities issues?** |  |  |

**Please email this form to:** **surveillance@nice.org.uk**

**Closing date: 5pm, Tuesday 24 October 2017**

**PLEASE NOTE:**

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, if NICE’s reasonable opinion is that the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.